ACG Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

ACG Wealth’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,201	Closed	-$122K	–	672
2022 Q2	$122K	Buy	+2,201	New	+$125K	0.02%	304

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

ACG Wealth's LGND Position: Q3 2022 in Review

ACG Wealth sold out of Ligand Pharmaceuticals (LGND) in Q3 2022, closing a stake of 2,201 shares — an estimated $122K sold.

ACG Wealth first reported a position in LGND in Q2 2022 and held it in 1 quarter. The position peaked at $122K in Q2 2022. 205 funds tracked by Wall St. Rank hold LGND as of Q3 2022.

ACG Wealth reported no remaining Ligand Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 2,201 Ligand Pharmaceuticals shares in Q3 2022, an estimated $122K.
ACG Wealth first reported a position in Ligand Pharmaceuticals in Q2 2022 and held it in 1 quarter.
ACG Wealth's Ligand Pharmaceuticals position peaked at $122K in Q2 2022.
205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.